Browsing Tag
monoclonal antibodies
8 posts
Is co-administered COVID prophylaxis with antibodies and mRNA vaccines the next FDA-backed model?
Invivyd’s LIBERTY trial explores co-administered COVID prevention with VYD2311 and mRNA vaccines. See how this could influence FDA and payer strategies.
Elanco (NYSE: ELAN) wins USDA nod for Befrena monoclonal antibody in canine dermatology
Elanco wins USDA approval for Befrena to treat canine dermatitis. Find out how this boosts its antibody strategy and reshapes competition in pet health.
Sanofi invests up to $1bn in South Korean biotech ADEL to advance tau-based Alzheimer’s therapy
Sanofi has signed an up to $1 billion Alzheimer’s drug deal with South Korean biotech ADEL. Find out what the tau targeting strategy means for investors and patients.
Can early LEQEMBI treatment delay Alzheimer’s by 8 years? Eisai reveals long-term data at CTAD 2025
Find out how Eisai and Biogen's LEQEMBI may slow Alzheimer’s by over 8 years in early-stage patients, as new CTAD 2025 data reveals long-term benefits.
Why Vir Biotechnology’s tobevibart and elebsiran combo may signal a breakthrough in hepatitis delta treatment
Vir Biotechnology’s hepatitis delta therapy shows 66% RNA clearance at 48 weeks. Find out why this could redefine treatment ahead of 2027 trial results.
Percheron Therapeutics (ASX: PER) licenses HMBD-002 cancer drug from Hummingbird in oncology pivot
Percheron Therapeutics acquires global rights to phase II-ready cancer drug HMBD-002 from Hummingbird Bioscience. Learn what this means for investors.
CSL wins FDA approval for ANDEMBRY, the first monthly anti-factor XIIa therapy for hereditary angioedema
CSL’s ANDEMBRY gains U.S. FDA approval as the first monthly HAE treatment targeting factor XIIa. Learn how it redefines disease control for patients.
Sanofi signs $1.45bn deal to acquire Kymab, expanding its immune-therapy pipeline
In a significant move to bolster its immuno-oncology and immune-mediated disease portfolio, Sanofi has acquired Kymab, a UK-based…